Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management | Zendy

Giulia Roda | Zendy; Bindia Jharap | Zendy; Neeraj Narula | Zendy; JeanFrédéric Colombel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management

Author(s) -

Giulia Roda,

Bindia Jharap,

Neeraj Narula,

JeanFrédéric Colombel

Publication year - 2016

Publication title -

clinical and translational gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.673

H-Index - 35

ISSN - 2155-384X

DOI - 10.1038/ctg.2015.63

Subject(s) - medicine , epidemiology , intensive care medicine , inflammatory response , medline , oncology , inflammation , political science , law

Tumor necrosis factor-α (TNFα) antagonists have advanced the management of inflammatory bowel diseases patients leading to an improvement of patient's quality of life with the reduction of number of surgeries and hospitalizations. Despite these advances, many patients do not respond to the induction therapy (primary non-response-PNR) or lose response during the treatment (secondary loss of response-LOR). In this paper we will provide an overview of the definition, epidemiology and risk factors for PNR and LOR, as well as discuss the therapeutic options for managing LOR.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research